4/6/2023 0 Comments Amitiza 24 mcg![]() Patients who experience dyspnea should inform their physician. This symptom generally resolves within three hours, but may recur with repeat dosing. Patients taking AMITIZA may experience dyspnea within an hour of first dose. Patients should be aware of the possible occurrence of diarrhea during treatment and inform their physician if the diarrhea becomes severe. Patients who experience severe nausea should inform their physician.ĪMITIZA should not be prescribed to patients that have severe diarrhea. If this occurs, concomitant administration of food with AMITIZA may reduce symptoms of nausea. Patients taking AMITIZA may experience nausea. Women who could become pregnant should have a negative pregnancy test prior to beginning therapy with AMITIZA and should be capable of complying with effective contraceptive measures. AMITIZA should be used during pregnancy only if the benefit justifies the potential risk to the fetus. The safety of AMITIZA in pregnancy has not been evaluated in humans. Patients with symptoms suggestive of mechanical gastrointestinal obstruction should be thoroughly evaluated by the treating physician to confirm the absence of such an obstruction prior to initiating AMITIZA treatment. IBS is approximately two to two-and-a-half times more prevalent in women than men.Ībout AMITIZA® (lubiprostone) for Chronic Idiopathic Constipation and IBS-C IndicationĪMITIZA® (lubiprostone) is indicated for the treatment of Chronic Idiopathic Constipation (24 mcg) in adults and for Irritable Bowel Syndrome with Constipation (8 mcg) in women ≥ 18 years old.ĪMITIZA is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction. Although people with IBS-C report many of the symptoms associated with constipation, the presence of abdominal discomfort or pain is what differentiates IBS-C from chronic constipation. In IBS-C, symptoms are present for at least 12 weeks (not necessarily consecutive) over a 12-month period. There are three main types of IBS: IBS with constipation (IBS-C), IBS with diarrhea (IBS-D) and IBS with mixed constipation and diarrhea (IBS-M). IBS is a disorder characterized by symptoms including abdominal discomfort or pain, bloating and changes of bowel habits such as constipation and/or diarrhea. ![]() by Sucampo Pharmaceuticals and Takeda Pharmaceuticals North America, Inc.Ībout Irritable Bowel Syndrome with Constipation (IBS-C) "I am very pleased with the quick commercial launch of AMITIZA 8 mcg for this particular indication as it could provide a treatment option to many adult women suffering from IBS-C," said Ryuji Ueno, M.D., Ph.D., Ph.D., founder, chairman and chief executive officer, Sucampo Pharmaceuticals.ĪMITIZA was developed by Sucampo Pharmaceuticals and is co-marketed in the U.S. "The availability of AMITIZA makes it possible for appropriate patients to receive a widely available prescription medication that can be an important tool to help treat this condition." "The effects of IBS-C can be debilitating and far-reaching-affecting many aspects of a person’s life," said Charles Baum, M.D., gastroenterologist, executive medical director, Gastroenterology and Internal Medicine, at Takeda Pharmaceuticals North America, Inc. Although it is not well understood how AMITIZA works to reduce symptoms in patients with IBS-C, ex vivo animal studies suggest that AMITIZA stimulates recovery of mucosal barrier function by restoring tight junction protein complexes. with IBS-C.ĪMITIZA has a mechanism of action that works locally in the intestine to increase fluid secretion, resulting in increased passage of stool and alleviating symptoms associated with Chronic Idiopathic Constipation. AMITIZA 24 mcg capsules have been available by prescription to treat Chronic Idiopathic Constipation in adults since 2006.ĪMITIZA is the only widely available FDA-approved prescription treatment option that can provide overall symptom relief for the millions of adult women in the U.S. for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in women 18 years and older. today announced that AMITIZA® (lubiprostone) 8 mcg capsules are now available by prescription in pharmacies across the U.S. ![]() (Nasdaq: SCMP) and Takeda Pharmaceuticals North America, Inc. AMITIZA 8 mcg dose is the only widely available FDA-approved prescription medication for Irritable Bowel Syndrome with Constipationīethesda, Md., and Deerfield, Ill., – Sucampo Pharmaceuticals, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |